Spatial heterogeneity of MRI response to first-line hormonal therapy to predict progression-free survival in metastatic breast cancer.

被引：0
|
作者：
Kosmin, Michael
Makris, Andreas
Sokhi, Heminder
Thijssen, Toon
Padhani, Anwar R.
机构：
[1] Mt Vernon Canc Ctr, Northwood, Middx, England
[2] Acad Oncol Unit, Pinner, England
[3] Paul Strickland Scanner Ctr, Northwood, Middx, England
[4] Paul Strickland Scanner Ctr, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e12544
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12544
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Spatial heterogeneity of response on whole-body MRI to first line hormonal therapy predicts progression-free survival in metastatic breast cancer
    Kosmin, Michael
    Makris, Andreas
    Sokhi, Heminder
    Thijssen, Toon
    Padhani, Anwar
    CANCER RESEARCH, 2018, 78 (04)
  • [2] A quantitative study of tumor response and progression-free survival as surrogate endpoints for overall survival in first-line treatment of metastatic breast cancer
    Burzykowski, T
    Piccart, MJ
    Sledge, G
    Carmichael, J
    Luck, HJ
    Mackey, JR
    Nabholtz, JM
    Paridaens, R
    Biganzoli, L
    Jassem, J
    Blohmer, JU
    Bontenbal, M
    Bonneterre, J
    Chan, S
    Atalay, G
    Therasse, P
    Buyse, M
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S277 - S278
  • [3] Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer
    Gradishar, William J.
    Krasnojon, Dimitry
    Cheporov, Sergey
    Makhson, Anatoly N.
    Manikhas, Georgiy M.
    Clawson, Alicia
    Bhar, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) : 3611 - 3619
  • [4] Progression-free survival as an endpoint for clinical trials in first-line metastatic urothelial cancer
    Galsky, Matt D.
    Krege, Susanne
    Lin, Chia-Chin
    Hahn, Noah M.
    Ecke, Thorsten
    Moshier, Erin L.
    Sonpavde, Guru
    Godbold, James H.
    Oh, William K.
    Bamias, Aristotelis
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [5] Improved progression-free survival from the addition of vinorelbine to epirubicin in first line chemotherapy of metastatic breast cancer.
    Ejlertsen, B
    Mouridsen, HT
    Langkjer, ST
    Andersen, J
    Sjostrom, J
    Kjaer, M
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 270 - 270
  • [6] Trastuzumab Beyond Progression for HER2 Positive Metastatic Breast Cancer: Progression-Free Survival on First-Line Therapy Predicts Overall Survival Impact
    Rayson, Daniel
    Lutes, Sarah
    Walsh, Gordon
    Sellon, Marlene
    Colwell, Bruce
    Dorreen, Mark
    Drucker, Arik
    Jeyakumar, Alwin
    Younis, Tallal
    BREAST JOURNAL, 2014, 20 (04): : 408 - 413
  • [7] Prolonged progression-free survival in metastatic breast cancer
    Mayor, Susan
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2008, 69 (07) : 378 - 378
  • [8] Improved progression-free survival in metastatic breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2018, 19 (02): : E79 - E79
  • [9] Bevacizumab as first-line therapy in metastatic renal cell carcinoma. Progression-free survival for 3 years
    Pichler, R.
    Horninger, W.
    Aigner, F.
    Heidegger, I.
    UROLOGE, 2016, 55 (03): : 381 - 385
  • [10] BEVACIZUMABIN AND FIRST-LINE CHEMOTHERAPY IN THE TREATMENT OF METASTATIC COLORECTAL CANCER: EVALUATION OF CLINICAL EFFICACY AND PROGRESSION-FREE SURVIVAL
    Liang, Jinhao
    Xiang, Chengjiang
    Sun, Ke
    FARMACIA, 2023, 71 (04) : 747 - 754
12345